The aim of this study was to measure the pretreatment serum levels of IL‐1β, IL‐6, TNFα in CRC patients and examine the relationship between these proinflammatory cytokines and the clinicopathologic features of CRC, especially progression‐free survival. The gene discussed is IL6; the disease is colorectal carcinoma.